NR1I2 and cancer: These metabolites act primarily through the aryl hydrocarbon receptor (AhR) and the PXR (52), and in GI cancers they may exert protective effects—for example, IAA and IPA can strengthen the epithelial barrier and suppress inflammation, thereby reducing cancer risk (53).